EUROVISCO consensus guidelines for the use of hyaluronic acid viscosupplementation in knee osteoarthritis based on patient characteristics

Conrozier, Thierry; Raman, Raghu; Diraçoglù, Demirhan; Montfort, Jordi; Bard, Hervé; Baron, Dominique; Gonçalves, Belarmino; Richette, Pascal; Migliore, Alberto; Chevalier, Xavier; Brittberg, Mats; Henrotin, Yves

doi:http://dx.doi.org/10.1177/19476035241271970

EUROVISCO consensus guidelines for the use of hyaluronic acid viscosupplementation in knee osteoarthritis based on patient characteristics

Llicència

Citació

Conrozier T, Raman R, Diraçoglu D, Montfort J, Bard H, Baron D, Goncalves B, Richette P, Migliore A, Chevalier X, Brittberg M, Henrotin Y. EUROVISCO consensus guidelines for the use of hyaluronic acid viscosupplementation in knee osteoarthritis based on patient characteristics. Cartilage. 2025;16(4):438-52. DOI: 10.1177/19476035241271970

Resum

Objectives: Viscosupplementation with hyaluronic acid (HA) is a commonly used intra-articular treatment for osteoarthritis (OA). We performed a Delphi consensus process to formulate guidelines for the use of intra-articular hyaluronic acid (IAHA) knee injection according to the patient’s characteristics. Methods: The EUROVISCO group consists of 12 members who had expertise in clinical and/or research in the field of OA and IAHA treatment. This group drafted issues through an iterative process and subsequently voted according to a Delphi process on their level of agreement (LoA) on these recommendations. The scores were pooled to generate a median agreement score for each recommendation. The strength of the recommendation (SOR) was classified as strong if the median agreement score was ≥8. The level of consensus (LOC) was also obtained. The level of evidence was given for each recommendation. Results: A total of 34 statements were evaluated by the expert group. A unanimous or high LoA was obtained in 16. IAHA can be considered irrespective of the age in patients with symptomatic knee OA. It can be used in patients with diabetes and/or moderate to severe obesity. It can also be used in knee OA patients with a history of gout, meniscocalcinosis and with mild-to-moderate varus/valgus malalignment. The group recommended against the use of VS in pregnant women and in OA flare. Conclusion: In summary, the working group provided strong recommendations for the use of IAHA injection that will facilitate individualized treatment decision algorithms in the management of knee OA.